In today’s briefing:
- Teladoc (TDOC US): Membership Add and Expanding Product Penetration to Drive 25–30% Top Line Growth
- Aier Eye Hospital Group (300015.CH) – More than Just Bribery Scandal
Teladoc (TDOC US): Membership Add and Expanding Product Penetration to Drive 25–30% Top Line Growth
- Teladoc Health, Inc. (TDOC US), the whole-person virtual care industry leader in scale, clinical breadth, and outcomes, reported 70% revenue CAGR over the last three years.
- The company expects 25% annual expansion in revenue per member, which together with 1–5% per year growth in membership will lead to 25–30% revenue CAGR during 2021–2024.
- Teladoc has a strong growth opportunity amid a large TAM of 298 million total insured lives in the U.S., of which the company has penetrated just 30%.
Aier Eye Hospital Group (300015.CH) – More than Just Bribery Scandal
- According to public news, the recent bribery scandal of Aier Eye Hospital Group (300015 CH) has raised widespread concern. Shenzhen stock Exchange also issued a letter of inquiry.
- The development model based on M&A funds helps rapid expansion, but also leads to profit orientation and large goodwill balance, indicating potential risks.
- The biggest risk is the revolutionary technology/drugs to disrupt the business value of Aier’s medical services. So, Aier could be a short-term trade, but not a long-term hold.
Before it’s here, it’s on Smartkarma
